Chad Terhune

Chad Terhune is an investigative reporter at Reuters based in Los Angeles. He has covered pharmaceutical companies and their interactions with regulators for more than a decade. Previously, he was a staff writer at the Los Angeles Times where he focused on health care, business and politics. Terhune graduated from the University of California, Berkeley with a degree in political science.

Biography:  https://finance.yahoo.com/news/exclusive-merck-anti-baldness-drug-044519208.html

78%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

100%

Examples:

  • Newly unsealed court documents and other records show that Merck & Co and U.S. regulators knew about reports of suicidal behavior in men taking the company's anti-baldness treatment Propecia when they decided not to warn consumers of those potential risks in a 2011 update of the popular drug's label.

Conflicts of Interest

100%

Examples:

  • Merck knew of more than 200 reports of depression, including suicidal thoughts, in men taking Propecia and decided there weren't enough specifics or reports to warrant more than 'routine monitoring'.
  • Since the 14 years the drug was on the market, the agency received 34 such reports, including 10 deaths. Before that, in the first 2 years of finasteride's existence, there were only about one-third as many suicides reported.

Contradictions

85%

Examples:

  • For Wegovy, 24.1% of patients persisted with therapy over two years without a gap of 60 days or more.
  • With Ozempic, which has the same active ingredient as Wegovy - semaglutide - 22.2% of patients kept filling their prescriptions at two years.

Deceptions

30%

Examples:

  • Only one in four U.S. patients were still taking Wegovy or Ozempic for weight loss two years later, according to an analysis of U.S. pharmacy claims provided to Reuters...
  • People want to provide obesity care to their employees, but they want to do it in a way that doesn't bankrupt them.

Recent Articles

GLP-1 Drugs: A Step Forward in Obesity Care but Not a Silver Bullet

GLP-1 Drugs: A Step Forward in Obesity Care but Not a Silver Bullet

Broke On: Wednesday, 10 July 2024 GLP-1 drugs like Ozempic and Wegovy offer weight loss benefits and health improvements, but they don't address the systemic issues in obesity care. A survey by Verywell Health revealed that many people face barriers to respectful care. Dr. Fatima Cody Stanford's research revolutionized obesity medicine with approved diabetes drugs for treating obesity. However, these drugs are not a long-term solution for weight loss or addressing underlying issues contributing to obesity.